184 related articles for article (PubMed ID: 36852700)
1. Hypermethylation-Mediated lncRNA MAGI2-AS3 Downregulation Facilitates Malignant Progression of Laryngeal Squamous Cell Carcinoma via Interacting With SPT6.
Wang J; Yang C; Cao H; Yang J; Meng W; Yu M; Yu L; Wang B
Cell Transplant; 2023; 32():9636897231154574. PubMed ID: 36852700
[TBL] [Abstract][Full Text] [Related]
2. Exosomal long noncoding RNAs MAGI2-AS3 and CCDC144NL-AS1 in oral squamous cell carcinoma development via the PI3K-AKT-mTOR signaling pathway.
Li C; Guo H; Xiong J; Feng B; Zhu P; Jiang W; Jiang P; Su X; Huang X
Pathol Res Pract; 2022 Dec; 240():154219. PubMed ID: 36401978
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation-mediated downregulation of the LINC01554 gene accelerates the malignant progression and regulates the chemosensitivity of laryngeal squamous cell carcinoma.
Wang J; Meng W; Yang J; Cao H; Liu T; Yang C; Yu M; Wang B
J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 35988928
[TBL] [Abstract][Full Text] [Related]
4. Roles of lncRNA MAGI2-AS3 in human cancers.
Kai-Xin L; Cheng C; Rui L; Zheng-Wei S; Wen-Wen T; Peng X
Biomed Pharmacother; 2021 Sep; 141():111812. PubMed ID: 34126355
[TBL] [Abstract][Full Text] [Related]
5. LncRNA MAGI2-AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR-374b-5p/SMG1 signaling pathway.
Yin Z; Ma T; Yan J; Shi N; Zhang C; Lu X; Hou B; Jian Z
J Cell Physiol; 2019 Aug; 234(10):18825-18836. PubMed ID: 30924168
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation‑mediated decrease of lncRNA HNF1A‑AS1 contributes to malignant progression of laryngeal squamous cell carcinoma via EMT.
Shi Y; Zhang Q; Xie M; Feng Y; Ma S; Yi C; Wang Z; Li Y; Liu X; Liu H; Yang H; Yan Y; Zhang Y; Ren X; Luo H
Oncol Rep; 2020 Dec; 44(6):2503-2516. PubMed ID: 33125127
[TBL] [Abstract][Full Text] [Related]
7. LncRNA MAGI2-AS3 is downregulated in the distant recurrence of hepatocellular carcinoma after surgical resection and affects migration and invasion via ROCK2.
Fang G; Wang J; Sun X; Xu R; Zhao X; Shao L; Sun C; Wang Y
Ann Hepatol; 2020; 19(5):535-540. PubMed ID: 32546442
[TBL] [Abstract][Full Text] [Related]
8. LncRNA MAGI2-AS3 is downregulated in non-small cell lung cancer and may be a sponge of miR-25.
Sui Y; Chi W; Feng L; Jiang J
BMC Pulm Med; 2020 Mar; 20(1):59. PubMed ID: 32138716
[TBL] [Abstract][Full Text] [Related]
9. lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axis.
Yang G; Li T; Liu J; Quan Z; Liu M; Guo Y; Wu Y; Ou L; Wu X; Zheng Y
Genomics; 2023 Mar; 115(2):110599. PubMed ID: 36889366
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA MAGI2-AS3 inhibits bladder cancer progression through MAGI2/PTEN/epithelial-mesenchymal transition (EMT) axis.
Shen D; Xu J; Cao X; Cao X; Tan H; Deng H
Cancer Biomark; 2021; 30(2):155-165. PubMed ID: 33104021
[TBL] [Abstract][Full Text] [Related]
11. LncRNA MAGI2-AS3 inhibites tumor progression by up-regulating STAM via interacting with miR-142-3p in clear cell renal cell carcinoma.
Yang R; Chen Z; Ao S; Liang L; Chen Z; Duan X; Zeng G; Deng T
Cell Signal; 2024 Jan; 113():110954. PubMed ID: 38084836
[TBL] [Abstract][Full Text] [Related]
12. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis.
Hao XZ; Yang K
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7399-7407. PubMed ID: 31539127
[TBL] [Abstract][Full Text] [Related]
13. LncRNA MAGI2-AS3 inhibits tumor progression and angiogenesis by regulating ACY1 via interacting with transcription factor HEY1 in clear cell renal cell carcinoma.
Wang G; Li H; Hou Y
Cancer Gene Ther; 2022 May; 29(5):585-596. PubMed ID: 34002044
[TBL] [Abstract][Full Text] [Related]
14. LncRNA MAGI2-AS3 inhibits bladder cancer progression by targeting the miR-31-5p/TNS1 axis.
Tang C; Cai Y; Jiang H; Lv Z; Yang C; Xu H; Li Z; Li Y
Aging (Albany NY); 2020 Nov; 12(24):25547-25563. PubMed ID: 33231563
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MAGI2-AS3 is down-regulated in intervertebral disc degeneration and participates in the regulation of FasL expression in nucleus pulposus cells.
Cui S; Liu Z; Tang B; Wang Z; Li B
BMC Musculoskelet Disord; 2020 Mar; 21(1):149. PubMed ID: 32143617
[TBL] [Abstract][Full Text] [Related]
16. LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia.
Chen L; Fan X; Zhu J; Chen X; Liu Y; Zhou H
RNA Biol; 2020 Jun; 17(6):784-793. PubMed ID: 32174258
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA MAGI2-AS3/miR-218-5p/GDPD5/SEC61A1 axis drives cellular proliferation and migration and confers cisplatin resistance in nasopharyngeal carcinoma.
Cao C; Zhou S; Hu J
Int Forum Allergy Rhinol; 2020 Aug; 10(8):1012-1023. PubMed ID: 32450008
[TBL] [Abstract][Full Text] [Related]
18. Novel insights for lncRNA MAGI2-AS3 in solid tumors.
Xue C; Li G; Lu J; Luo J; Jia J
Biomed Pharmacother; 2021 May; 137():111429. PubMed ID: 33761624
[TBL] [Abstract][Full Text] [Related]
19. LncRNA
Li F; Hu Q; Pang Z; Xu X
Cancer Biother Radiopharm; 2020 Feb; 35(1):72-76. PubMed ID: 31910343
[No Abstract] [Full Text] [Related]
20. MAGI2-AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2.
Xu X; Yuan X; Ni J; Guo J; Gao Y; Yin W; Li F; Wei L; Zhang J
J Cell Physiol; 2021 Feb; 236(2):1116-1130. PubMed ID: 32730644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
